Implications: These findings raise the possibility of a unique therapeutic approach for 70 GBM, involving MNK1 targeting to sensitize MES GSCs to drugs like arsenic trioxide.
ATO has shown pre-clinical efficacy against GSCs through several mechanisms 92 including activation of apoptosis and autophagy, degradation of the PML protein, and investigation in a phase I/II clinical trial in GBM (9, 10). Given this information, we 95 sought to uncover the mechanisms that drive differential ATO responses in GBM. 96 Translation is the most energetically demanding process in the cell and is an 97 emerging resistance mechanism in cancer (11, 12). The MAPK-interacting kinases 98 (MNKs) regulate initiation of cap-dependent translation through phosphorylation of the 99 mRNA-binding protein, eukaryotic translation initiation factor 4E (eIF4E) (13, 14) . After 100 activation of upstream MAPK signaling through either p38 or ERK, MNK binds to the 101 eukaryotic translation initiation factor 4G (eIF4G), facilitating phosphorylation of eIF4E 102 and translation of eIF4E-sensitive mRNAs, many of which include potent oncogenes 103 (15). Several stimuli can activate this signaling cascade including hypotonic stress, 104 radiation, interferon signaling, and chemotherapy (16, 17). Activation of translation 105 allows the cell to adapt to stressful stimuli and is a mechanism of resistance in cancer 106 (16, 18). In GBM, MNK signaling and mRNA translation have been implicated in 107 resistance to the alkylating agent, temozolomide, as well as radiation (19, 20) . 108 Furthermore, we previously demonstrated that MNK activation is particularly important 109 for the maintenance of therapy-resistant MES GSCs (21). 110 Here, we explored the role of MNK signaling in the regulation of ATO responses 111 in established GBM models and patient-derived MES and PN GSC lines. We found that 112 ATO activates MNK-eIF4E in GBM cells and that, in an intracranial PDX model of GBM, 113 MNK activation correlates with ATO resistance. Such resistance is likely mediated by 114 MNK1, to which ATO directly binds, increasing kinase activity. Given that MNK directly 115 regulates translational activation, we tested the effect of ATO on translation in a GBM (Fig. 1A) . We then tested the Table S1 ).
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To expand upon these findings, we tested a subset of these compounds in two 285 MES and three PN GBM cell lines at three different concentrations and once again 286 found that PN GBM cells are more sensitive to ATO than MES GBM cells ( Fig. 1D-E; 287 Table S2 ). The normalized cell viabilities after treatment with each compound were 288 compared between MES and PN GBM cells and only 28 of the 120 tested compounds, 289 including ATO, were found to be statistically significant at an FDR adjusted P-value < 290 0.05. Other cytotoxic agents were also found to be more effective in PN GBM, including 291 temozolomide (TMZ), the standard-of-care chemotherapy used for the treatment of 292 GBM (Fig. S1 ). Next, we tested ATO in a dose-response experiment and found similar 293 results, validating our high-throughput screen (Fig. 1F ). Finally, we tested the effect of 294 ATO on patient-derived MES and PN GSC lines. We found that MES GSCs are 295 resistant to and PN GSCs are sensitive to low-dose ATO (Fig. 1G ).
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As ATO treatment has been shown to activate MNK and several upstream 297 kinases (MAPKs, MAPKKs, and MAPKKKs) leading to therapeutic resistance (28-34), 298 we sought to determine whether this mechanism regulated ATO responses in GBM. 3A-D). We also found that ATO activates MNK activity in LN229 cells (which express 337 MNK1 and MNK2) but not in LN18 cells (MNK1 below detectable levels) (Fig. 3E ).
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These results support a conclusion that GBM cells depend upon MNK1 for activation of 339 eIF4E phosphorylation after ATO treatment. four in close proximity, which may facilitate binding for arsenic. We used a previously 346 described trivalent arsenic-biotin conjugate (As-Biotin) to determine whether arsenic 347 binds MNK1 (23). We treated GBM cells or recombinant MNK1 protein with or without 348 As-Biotin, and used streptavidin beads to pull-down biotinylated conjugates. In both 349 cases, substantial amounts of MNK1 were found only in the As-Biotin treated samples 350 suggesting that the arsenic compound bound to MNK1 (Fig. 3F ). Next, we used an in (Fig. 4C) . We found that a number of coding genes were 378 significantly increased in the polysomal as compared to total fractions (Fig. 4D ). In the 379 ATO treated polysomes, 96 transcripts were significantly upregulated, with 51 of these 380 transcripts found in the ATO treated polysomes but not in the untreated polysomes 381 (Table S3) . Of these transcripts, Frizzled Class Receptor 6 (FZD6) a master regulator 382 of the MES phenotype in GSCs (39), was enriched in ATO treated polysomes. The 383 upregulation of FZD6 was confirmed by qRT-PCR (Fig. 4E) . Importantly, no change in 384 FZD6 was observed in the total mRNA fractions. 385 We next sought to define the genes enriched in the ATO polysomes as 386 compared with the untreated polysomes. Using Gene Set Enrichment Analysis (GSEA), 387 we found numerous gene sets significantly enriched in the ATO polysomes. Among the 388 top ten Gene Ontology (GO) gene sets, three were involved in the inhibition of 389 apoptosis (Fig. 4F) . These findings suggest that ATO treatment activates translation of 390 anti-apoptotic genes, preventing cell death and promoting resistance in MES GBM. MKNK1 expression in GBM when compared with low-grade gliomas (Fig. 5D) . In low-407 grade gliomas, high MKNK1 expression predicts poor prognosis (Fig. 5E) . Similarly, we 408 found that high MKNK1 expression predicts poor prognosis in GBM patients (Fig. 5F ). 
MNK inhibition sensitizes MES GSCs to ATO

418
We next examined the effect of ATO on patient-derived MES GSCs. GSCs are 419 known to be particularly resistant to conventional therapies (2). We found that ATO 420 treatment induces eIF4E phosphorylation in a MES GSC line (Fig. 6A) . As with 421 established GBM cells (Fig. 2) , MNK inhibition blocked ATO-induced eIF4E 422 phosphorylation in MES GSCs (Fig. 6B) . Building upon our previous finding that ATO 423 treatment activates translation of anti-apoptotic mRNAs in GBM (Fig. 4) , we next tested 424 whether MNK inhibition could sensitize MES GSCs to ATO and induce apoptosis. We 425 found that concomitant treatment with ATO and a MNK inhibitor led to an increase in 426 apoptosis ( Fig. 6C-E) . Furthermore, treatment of MES GSCs with ATO and a MNK 427 inhibitor led to a significant decrease in neurosphere formation indicating depletion of 428 the CSC populations (Fig. 6F) (Fig. 7A) . samples also exhibit higher MNK activity and translational activation. 450 We also found that MES subtype GBM from this cohort had significantly higher 451 eIF4E phosphorylation than the PN subtype, suggesting that MNK is highly activated in 452 the MES subtype (Fig. 7E-F) . Furthermore, enrichment of the MES gene set positively 453 correlated with eIF4E phosphorylation (Fig. 7G) 
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